S&P 500   4,431.85 (+2.43%)
DOW   34,725.47 (+1.65%)
QQQ   351.80 (+3.14%)
AAPL   170.33 (+6.98%)
MSFT   308.26 (+2.81%)
FB   301.71 (+2.40%)
GOOGL   2,667.02 (+3.37%)
AMZN   2,879.56 (+3.11%)
TSLA   846.35 (+2.08%)
NVDA   228.40 (+4.08%)
BABA   115.23 (+3.08%)
NIO   20.90 (-0.99%)
AMD   105.24 (+2.57%)
CGC   7.27 (+6.13%)
MU   79.27 (+0.70%)
GE   92.10 (+2.45%)
T   25.21 (+4.52%)
F   19.54 (-0.05%)
DIS   138.63 (+2.37%)
AMC   15.06 (+3.72%)
PFE   54.33 (+1.80%)
ACB   3.91 (+3.17%)
BA   190.57 (+0.43%)
S&P 500   4,431.85 (+2.43%)
DOW   34,725.47 (+1.65%)
QQQ   351.80 (+3.14%)
AAPL   170.33 (+6.98%)
MSFT   308.26 (+2.81%)
FB   301.71 (+2.40%)
GOOGL   2,667.02 (+3.37%)
AMZN   2,879.56 (+3.11%)
TSLA   846.35 (+2.08%)
NVDA   228.40 (+4.08%)
BABA   115.23 (+3.08%)
NIO   20.90 (-0.99%)
AMD   105.24 (+2.57%)
CGC   7.27 (+6.13%)
MU   79.27 (+0.70%)
GE   92.10 (+2.45%)
T   25.21 (+4.52%)
F   19.54 (-0.05%)
DIS   138.63 (+2.37%)
AMC   15.06 (+3.72%)
PFE   54.33 (+1.80%)
ACB   3.91 (+3.17%)
BA   190.57 (+0.43%)
S&P 500   4,431.85 (+2.43%)
DOW   34,725.47 (+1.65%)
QQQ   351.80 (+3.14%)
AAPL   170.33 (+6.98%)
MSFT   308.26 (+2.81%)
FB   301.71 (+2.40%)
GOOGL   2,667.02 (+3.37%)
AMZN   2,879.56 (+3.11%)
TSLA   846.35 (+2.08%)
NVDA   228.40 (+4.08%)
BABA   115.23 (+3.08%)
NIO   20.90 (-0.99%)
AMD   105.24 (+2.57%)
CGC   7.27 (+6.13%)
MU   79.27 (+0.70%)
GE   92.10 (+2.45%)
T   25.21 (+4.52%)
F   19.54 (-0.05%)
DIS   138.63 (+2.37%)
AMC   15.06 (+3.72%)
PFE   54.33 (+1.80%)
ACB   3.91 (+3.17%)
BA   190.57 (+0.43%)
S&P 500   4,431.85 (+2.43%)
DOW   34,725.47 (+1.65%)
QQQ   351.80 (+3.14%)
AAPL   170.33 (+6.98%)
MSFT   308.26 (+2.81%)
FB   301.71 (+2.40%)
GOOGL   2,667.02 (+3.37%)
AMZN   2,879.56 (+3.11%)
TSLA   846.35 (+2.08%)
NVDA   228.40 (+4.08%)
BABA   115.23 (+3.08%)
NIO   20.90 (-0.99%)
AMD   105.24 (+2.57%)
CGC   7.27 (+6.13%)
MU   79.27 (+0.70%)
GE   92.10 (+2.45%)
T   25.21 (+4.52%)
F   19.54 (-0.05%)
DIS   138.63 (+2.37%)
AMC   15.06 (+3.72%)
PFE   54.33 (+1.80%)
ACB   3.91 (+3.17%)
BA   190.57 (+0.43%)

Compare Stocks

Enter up to ten stock symbols separated by a comma or space (ex. PFE).

Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
PFE
Pfizer
$54.33
+1.8%
$55.14
$33.36
$61.71
$304.95B0.6938.93 million shs28.58 million shs

MarketRank™

CompanyOverall ScoreAnalyst's OpinionCommunity RankDividend StrengthCompany OwnershipEarnings & Valuation
PFE
Pfizer
3.50 of 5 Stars
2.34.84.22.53.8

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
PFE
Pfizer
2.55
Buy$57.636.08% Upside

Current Analyst Ratings

Latest PFE Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
1/28/2022
PFE
Pfizer
JPMorgan Chase & Co.
Boost Price Target$53.00 ➝ $57.00
1/14/2022
PFE
Pfizer
BMO Capital Markets
Boost Price Target$60.00 ➝ $76.00
1/11/2022
PFE
Pfizer
Barclays
Set Price Target$54.00
1/10/2022
PFE
Pfizer
The Goldman Sachs Group
Set Price Target$51.00
1/7/2022
PFE
Pfizer
Wells Fargo & Company
Boost Price TargetOverweight$60.00 ➝ $65.00
1/5/2022
PFE
Pfizer
Bank of America
UpgradeNeutral ➝ Buy$59.00 ➝ $70.00
1/4/2022
PFE
Pfizer
The Goldman Sachs Group
Set Price Target$51.00
1/4/2022
PFE
Pfizer
Barclays
Set Price Target$54.00
1/3/2022
PFE
Pfizer
Sanford C. Bernstein
Boost Price TargetMarket Perform$44.00 ➝ $65.00
12/29/2021
PFE
Pfizer
The Goldman Sachs Group
Set Price Target$51.00
(Data available from 1/28/2019 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
PFE
Pfizer
$41.91B7.28$3.07 per share17.67$11.42 per share4.76

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
PFE
Pfizer
$9.62B$3.3616.178.910.7227.66%30.70%12.92%2/8/2022 (Confirmed)

Latest PFE Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
2/8/2022N/A
PFE
Pfizer
$0.88N/A-$0.88N/AN/AN/A  
11/2/20219/30/2021
PFE
Pfizer
$1.08$1.34+$0.26$1.26$22.82 billion$24.09 billion    
(Earnings results data provided by Zacks Investment Research)

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
PFE
Pfizer
$1.562.87%+14.71%46.43%12 Years

Latest PFE Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
12/10/2021
PFE
Pfizer
quarterly$0.403.05%1/27/20221/28/20223/4/2022
(Data available from 1/1/2013 forward)

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
PFE
Pfizer
0.48
1.39
1.18

Ownership

Institutional Ownership

CompanyInstitutional Ownership
PFE
Pfizer
64.88%

Insider Ownership

CompanyInsider Ownership
PFE
Pfizer
0.05%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
PFE
Pfizer
78,5005.61 billion5.61 billionOptionable

PFE Headlines

SourceHeadline
Pfizers Sally Susman On Adaptability And Taking The Leap Into Social Media With Pharma - PRovoke MediaPfizer's Sally Susman On Adaptability And Taking The Leap Into Social Media With Pharma - PRovoke Media
provokemedia.com - January 28 at 9:08 PM
Delta variant, waning immunity reduced Pfizer vaccines effectiveness against household transmission - Yale NewsDelta variant, waning immunity reduced Pfizer vaccine's effectiveness against household transmission - Yale News
ysph.yale.edu - January 28 at 9:08 PM
Britain to start rolling out Pfizer COVID pill next month - ReutersBritain to start rolling out Pfizer COVID pill next month - Reuters
reuters.com - January 28 at 9:08 PM
COVID antiviral pills work against Omicron—when people can get them - Popular ScienceCOVID antiviral pills work against Omicron—when people can get them - Popular Science
popsci.com - January 28 at 4:07 PM
EU executive rebuked for not disclosing Von der Leyen-Pfizer texts - The GuardianEU executive rebuked for not disclosing Von der Leyen-Pfizer texts - The Guardian
theguardian.com - January 28 at 4:07 PM
Is Pfizer About to Have Another Megablockbuster Drug in Its Lineup? - Motley FoolIs Pfizer About to Have Another Megablockbuster Drug in Its Lineup? - Motley Fool
fool.com - January 28 at 4:07 PM
U.K. Set to Start Giving Pfizer Covid Pill to Vulnerable People - BloombergU.K. Set to Start Giving Pfizer Covid Pill to Vulnerable People - Bloomberg
bloomberg.com - January 28 at 4:07 PM
Pfizers Lorlatinib Scores European Approval In ALK-Positive Lung CancerPfizer's Lorlatinib Scores European Approval In ALK-Positive Lung Cancer
benzinga.com - January 28 at 1:11 PM
This Clinical Respiratory Company Has Been Easing the Burden on the Healthcare System During the Pandemic — Its Looking to Continue to Do So BeyondThis Clinical Respiratory Company Has Been Easing the Burden on the Healthcare System During the Pandemic — It's Looking to Continue to Do So Beyond
benzinga.com - January 28 at 1:11 PM
European Commission Approves LORVIQUA® (lorlatinib) as a First-Line Treatment for ALK-Positive Advanced Lung CancerEuropean Commission Approves LORVIQUA® (lorlatinib) as a First-Line Treatment for ALK-Positive Advanced Lung Cancer
finance.yahoo.com - January 28 at 10:02 AM
Nepal likely to get 6.2 million Pfizer doses from COVAX - The Kathmandu PostNepal likely to get 6.2 million Pfizer doses from COVAX - The Kathmandu Post
kathmandupost.com - January 28 at 5:01 AM
EUs Von Der Leyen Told to Look, Again, for Pfizer Vaccine Texts - BloombergEU's Von Der Leyen Told to Look, Again, for Pfizer Vaccine Texts - Bloomberg
bloomberg.com - January 28 at 5:01 AM
Free Pfizer COVID-19 vaccine event to be held Saturday - Martinsburg JournalFree Pfizer COVID-19 vaccine event to be held Saturday - Martinsburg Journal
journal-news.net - January 27 at 11:30 PM
EU drug watchdog approves Pfizers Covid-19 pill - FRANCE 24 EnglishEU drug watchdog approves Pfizer's Covid-19 pill - FRANCE 24 English
france24.com - January 27 at 11:30 PM
EU regulator recommends Pfizer’s COVID pill be authorized - The Seattle TimesEU regulator recommends Pfizer’s COVID pill be authorized - The Seattle Times
seattletimes.com - January 27 at 6:29 PM
Pfizer in Texas showdown: Court hearing this week will decide if it can assist FDA in providing COVID documents - FiercePharmaPfizer in Texas showdown: Court hearing this week will decide if it can assist FDA in providing COVID documents - FiercePharma
fiercepharma.com - January 27 at 6:29 PM
Covid vaccine: The side effect appearing up to 1 month after getting the Pfizer booster - ExpressCovid vaccine: The side effect appearing up to '1 month' after getting the Pfizer booster - Express
express.co.uk - January 27 at 1:29 PM
Woman in Australia reports experiencing awkward ‘headlight’ issue after getting Pfizer vaccine - New York Post Woman in Australia reports experiencing awkward ‘headlight’ issue after getting Pfizer vaccine - New York Post
nypost.com - January 27 at 1:29 PM
EU regulator recommends Pfizers COVID pill be authorized - ABC NewsEU regulator recommends Pfizer's COVID pill be authorized - ABC News
abcnews.go.com - January 27 at 1:29 PM
Pfizer Receives CHMP Positive Opinion for Novel COVID-19 Oral TreatmentPfizer Receives CHMP Positive Opinion for Novel COVID-19 Oral Treatment
finance.yahoo.com - January 27 at 1:29 PM
Pfizer (PFE), BioNTech Begin Omicron-Based COVID-19 Jab StudyPfizer (PFE), BioNTech Begin Omicron-Based COVID-19 Jab Study
finance.yahoo.com - January 27 at 1:29 PM
MarketingRx roundup: Pfizer debuts Prevnar 20 TV ads; Lilly gets first FDA 2022 promo slap down letter - Endpoints NewsMarketingRx roundup: Pfizer debuts Prevnar 20 TV ads; Lilly gets first FDA 2022 promo slap down letter - Endpoints News
endpts.com - January 27 at 1:38 AM
Pfizer CEO Albert Bourla is working to preserve Jewish history -  The Jerusalem PostPfizer CEO Albert Bourla is working to preserve Jewish history - The Jerusalem Post
jpost.com - January 27 at 1:38 AM
Covid pills: How to get Pfizer or Merck pill after testing positive - NBC NewsCovid pills: How to get Pfizer or Merck pill after testing positive - NBC News
nbcnews.com - January 26 at 8:37 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.